Invention Grant
US08389493B2 Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
有权
用于预防和/或逆转新发型自身免疫性糖尿病的基于微球的组合物
- Patent Title: Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
- Patent Title (中): 用于预防和/或逆转新发型自身免疫性糖尿病的基于微球的组合物
-
Application No.: US13103433Application Date: 2011-05-09
-
Publication No.: US08389493B2Publication Date: 2013-03-05
- Inventor: Larry R. Brown , Nick Giannoukakis , Kimberly A. Gillis , Massimo Trucco
- Applicant: Larry R. Brown , Nick Giannoukakis , Kimberly A. Gillis , Massimo Trucco
- Applicant Address: US IL Deerfield CH Glattpark (Opfikon) US PA Pittsburgh
- Assignee: Baxter International Inc.,Baxter Healthcare SA,University of Pittsburgh—of The Commonwealth System of Higher Education
- Current Assignee: Baxter International Inc.,Baxter Healthcare SA,University of Pittsburgh—of The Commonwealth System of Higher Education
- Current Assignee Address: US IL Deerfield CH Glattpark (Opfikon) US PA Pittsburgh
- Agency: Marshall, Gerstein & Borun, LLP
- Main IPC: A61K48/00
- IPC: A61K48/00
Abstract:
AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to reverse an autoimmune diabetes condition in NOD mice in vivo. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.
Public/Granted literature
- US20110274758A1 MICROSPHERE-BASED COMPOSITION FOR PREVENTING AND/OR REVERSING NEW-ONSET AUTOIMMUNE DIABETES Public/Granted day:2011-11-10
Information query
